Some patients — often those who are older — decide that the risk of side effects outweighs the benefits of treatment. These patients may choose not to treat their advanced prostate cancer.

AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A recent study found that AI can identify patients who will ...

President Joe Biden’s diagnosis of aggressive prostate cancer has brought the disease into the spotlight nationwide. Now local patients and doctors are speaking up to educate their community.

In this moment, patients like Mr. Biden and others who develop metastatic prostate cancer diagnoses are more fortunate than patients in the past. There are about 10 new treatments for the disease ...

The Decipher Prostate test’s clinical validity and clinical utility for use in patients with metastatic prostate cancer have been demonstrated in multiple, prospective, Phase 3 clinical studies ...

The first patient with prostate cancer has been enrolled in the recently launched clinical utility study (NCT06678828) of ClarityDX Prostate. 1 The randomized, 2-arm, control trial, which is ...

This is the first of two articles on a study of interactions between patients with prostate cancer and their healthcare teams across their cancer journey, with a focus on treatment decision making.

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...

Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients eligible to receive Pluvicto, is based on the Phase 3 PSMAfore trial results.

A 68-year-old man with prostate cancer developed penile metastasis, a rare but serious complication, reinforcing the need for thorough examination and early detection.

The trial utilizes the ArteraAI Prostate Test to enable treatment personalization by determining cancer metastasis risk and identifying whether patients may be able to reduce or avoid hormone therapy.